Are you Dr. Arrowsmith?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 105 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
605 Glenwood Avenue
Suite 200
Chattanooga, TN 37404Phone+1 423-698-1844Fax+1 423-624-2226
Summary
- Dr. Edward Arrowsmith, MD is an oncologist in Chattanooga, Tennessee. He is currently licensed to practice medicine in Tennessee and Georgia. He is affiliated with CHI Memorial and Parkridge Medical Center.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1999- Vanderbilt University Medical CenterResidency, Internal Medicine, 1992 - 1995
Vanderbilt University School of MedicineClass of 1992
Certifications & Licensure
TN State Medical License 1995 - 2026
GA State Medical License 2000 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Clinical Trials
- Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29
- Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Start of enrollment: 2019 Feb 12
Publications & Presentations
PubMed
- 50 citationsPhase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinoteca...Kimmie Ng, Josep Tabernero, Jimmy J. Hwang, Emilio Bajetta, Sunil Sharma
Clinical Cancer Research. 2013-07-15 - 57 citationsSafety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison
Journal for Immunotherapy of Cancer. 2022-02-01 - 45 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Nicholas J Vogelzang, Mark R Olsen, Joshua J McFarlane, Edward Arrowsmith, Todd M Bauer
Clinical Genitourinary Cancer. 2020-12-01
